Peptide-Based Therapeutic Approaches in Depression: Clinical Perspectives for 2025

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Reassessing the Neurochemical Hypothesis

For decades, the dominant paradigm in psychiatry has been the “chemical imbalance” hypothesis, which suggested that disruptions in neurotransmitters such as serotonin, norepinephrine, and dopamine were the primary cause of depressive disorders. Based on this assumption, therapeutic strategies centered on restoring these neurotransmitters to optimal levels. This framework led to the widespread prescription of selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants.

Initially, these pharmacologic agents were reported to achieve 80–90% efficacy in clinical trials. However, subsequent research has shown that SSRIs and related agents often perform no better than placebo in many patients. This revelation has prompted the search for alternative therapeutic pathways, including neuromodulation therapies, ketamine-based interventions, and peptide-focused strategies.

Neuropeptides and Mood Regulation

Neuropeptides—small protein-like signaling molecules active within the central nervous system—are increasingly recognized as critical modulators of affective states. Unlike the classical neurotransmitters they influence, neuropeptides provide regulatory control over monoaminergic transmission, shaping serotonergic, dopaminergic, and noradrenergic signaling.

Dysfunction in neuropeptide signaling has been implicated in several psychiatric disorders, including depression and schizophrenia. Clinical and preclinical data suggest that abnormalities in systems involving vasopressin, galanin, neuropeptide Y, and corticotropin-releasing factor may contribute to the development of mood and psychotic disorders.

Interestingly, electroconvulsive therapy (ECT)—a well-established intervention for treatment-resistant depression—alters levels of multiple neuropeptides, including galanin, neuropeptide Y, and somatostatin. This raises the possibility that ECT’s efficacy may be mediated, at least in part, through peptide modulation.

Emerging Peptides of Interest

Ghrelin and Its Analogues

Ghrelin, commonly known for its role in appetite regulation and growth hormone release, has demonstrated intrinsic antidepressant properties. Elevated ghrelin levels appear to counteract stress-induced increases in cortisol, a hormone strongly associated with depressive pathology. Animal studies show that activation of ghrelin receptors can reduce depressive-like behaviors and normalize stress responses.

Synthetic ghrelin receptor agonists, including ipamorelin, GHRP-2, and GHRP-6, have primarily been studied for their roles in growth hormone stimulation and tissue repair. However, preliminary findings suggest potential central nervous system benefits that warrant further investigation.

Melanocyte-Stimulating Hormone–Release Inhibiting Factor (MIF-1)

MIF-1, a synthetic tripeptide derived from the oxytocin precursor, has been studied since the 1970s. It demonstrates a dose-dependent effect in depressive states: low doses significantly reduce depressive symptoms, while higher doses appear less effective. Clinical studies have reported rapid improvements in mood with subcutaneous administration at low concentrations, with response rates far exceeding those of placebo groups. These findings highlight MIF-1’s potential as a novel therapeutic candidate.

Selank

Depression frequently coexists with anxiety, and both disorders are associated with inflammatory processes. Interleukin-6 (IL-6), a pro-inflammatory cytokine, is consistently elevated in individuals with anxiety-depressive syndromes and in conditions such as fibromyalgia and chronic fatigue syndrome. Selank, a synthetic heptapeptide, has been shown to downregulate IL-6 gene expression, thereby offering potential benefits for patients with inflammation-driven mood disturbances.

Semax

Brain-derived neurotrophic factor (BDNF) plays a crucial role in neuronal survival, synaptic plasticity, and cognitive function. Reduced BDNF levels have been strongly associated with depressive disorders and suicidality.

Semax, a synthetic derivative of adrenocorticotropic hormone, has been shown in animal models to increase BDNF expression in brain regions associated with mood regulation. Administration of BDNF itself has been observed to enhance exploratory behavior and reduce depression- and anxiety-like symptoms in rodents. These findings suggest that Semax may serve as a therapeutic tool for restoring neurotrophic balance in mood disorders and possibly in conditions such as ADHD.

Clinical Implications and Future Directions

While traditional pharmacologic agents targeting monoamine pathways have plateaued in efficacy, the exploration of neuropeptides offers a promising frontier in the treatment of depression. Evidence from preclinical and early clinical studies suggests that compounds such as ghrelin analogues, MIF-1, Selank, and Semax may provide symptom relief through mechanisms distinct from conventional antidepressants.

Current research remains in early phases, with limited large-scale clinical trials available. However, the relatively favorable safety profiles and novel mechanisms of action position peptide-based therapies as strong candidates for future development. Further research is essential to clarify dosing strategies, long-term efficacy, and the patient populations most likely to benefit.

REFERENCES

1. Tsai S. J. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical hypotheses, 68(5), 1144–1146. https://doi.org/10.1016/j.mehy.2006.07.017
2. Pae C. U. (2008). Therapeutic possibility of “Semax” for depression. CNS spectrums, 13(1), 20–21. https://doi.org/10.1017/s1092852900016102
3. Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA, 303(1), 47–53. https://doi.org/10.1001/jama.2009.1943
4. Madaan, V., & Wilson, D. R. (2009). Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug news & perspectives, 22(6), 319–324. https://doi.org/10.1358/dnp.2009.22.6.1395255
5. Masule, M. V., Rathod, S., Agrawal, Y., Patil, C. R., Nakhate, K. T., Ojha, S., Goyal, S. N., & Mahajan, U. B. (2022). Ghrelin mediated regulation of neurosynaptic transmitters in depressive disorders. Current research in pharmacology and drug discovery, 3, 100113. https://doi.org/10.1016/j.crphar.2022.100113
6. Uchakina, O. N., Uchakin, P. N., Miasoedov, N. F., Andreeva, L. A., Shcherbenko, V. E., Mezentseva, M. V., Gabaeva, M. V., Sokolov, O. I.u, Zozulia, A. A., & Ershov, F. I. (2008). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 108(5), 71–75.
7. Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. I.u, Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 93(6), 661–669.
8. Khavinson, V. K.h, Lin’kova, N. S., Tarnovskaya, S. I., Umnov, R. S., Elashkina, E. V., & Durnova, A. O. (2014). Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of experimental biology and medicine, 157(1), 77–80. https://doi.org/10.1007/s10517-014-2496-y
9. Liu, Y. L., Xu, J. J., Han, L. R., Liu, X. F., Lin, M. H., Wang, Y., Xiao, Z., Huang, Y. K., Ren, P., & Huang, X. (2023). Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry. Chinese journal of integrative medicine, 29(6), 490–499. https://doi.org/10.1007/s11655-022-3308-2